Download presentation
Presentation is loading. Please wait.
1
Targeting Thyroid Cancer
2
Program Goal
3
Thyroid Cancer Newly Detected 2013 (n=60,220)
4
Follicular Cell Thyroid Cancer Deaths 2013 (n = 1850)
5
Familial Syndromes
6
Thyroid Cancer Treatment “Pyramid”
7
Risk Stratification
10
RAI-Refractory Disease
11
Doxorubicin: Single-agent Activity
12
Doxorubicin +/- Cisplatin
13
Doxorubicin +/- Cisplatin: Results
15
Targets in Thyroid Cancer
16
VEGF and Thyroid Cancer
17
Sorafenib
18
Sorafenib University of Pennsylvania
19
Sorafenib Results University of Pennsylvania
20
Sorafenib Ohio State
21
Sorafenib Results Ohio State
22
Sorafenib Response Rates Ohio State vs Penn
23
DECISION Study
24
DECISION Study Results
25
DECISION Study Response Rates
26
Lenvatinib (E7080) Background
27
Lenvatinib Response Rate
28
Differentiated Thyroid Cancers Phase 2 Studies -- Multitargeted TKIs
29
Summary of Angiogenesis Inhibition
30
Genetic Alterations in Thyroid Cancer
31
Concordance of Genetic Alterations in MAPK but Not PI3K Pathway Oncogenes
32
Selumetinib (AZD6244)
33
Selumetinib Response Rate
35
Impact of Selumetinib on 124I Incorporation
37
Responses for RAI-Treated Patients
38
BRAF
39
Vemurafenib
40
Vemurafenib Response Rate
41
Current Studies for BRAF Mutant Thyroid Cancer
42
Summary of BRAF and MEK targets
43
Medullary Thyroid Cancer
44
Presentations of MCT
45
MTC: Hereditary vs Sporadic?
46
Hereditary MTC Until Proven Otherwise
47
Sporadic MTC Frequency of RET Mutations
48
Vandetanib (ZD6474)
49
Vandetanib: Randomized Phase 3 Trial
50
Vandetanib: PFS
51
Vandetanib: Objective Tumor Assessments
52
Cabozantinib (XL184)
53
Cabozantinib: Phase 3 Study Design (EXAM)
54
Cabozantinib: PFS
55
Summary of Medullary Thyroid Cancer
56
Abbreviations
57
Abbreviations (cont)
58
Abbreviations (cont)
59
References
60
References (cont)
61
References (cont)
62
References (cont)
63
References (cont)
64
References (cont)
65
References (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.